Jonathan Zalevsky

5.2k total citations · 1 hit paper
67 papers, 3.3k citations indexed

About

Jonathan Zalevsky is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jonathan Zalevsky has authored 67 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 42 papers in Immunology and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jonathan Zalevsky's work include CAR-T cell therapy research (25 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Immune Cell Function and Interaction (21 papers). Jonathan Zalevsky is often cited by papers focused on CAR-T cell therapy research (25 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Immune Cell Function and Interaction (21 papers). Jonathan Zalevsky collaborates with scholars based in United States, France and Italy. Jonathan Zalevsky's co-authors include R. Dyche Mullins, Kathryn DeFea, Mark S. Thoma, Nigel W. Bunnett, Olivier Déry, John R. Desjarlais, Irene Leung, Anne M. Villeneuve, Sher Karki and Holly M. Horton and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Jonathan Zalevsky

66 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2

2000 679 citations Jonathan Zalevsky, R. Dyche Mullins et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Zalevsky United States	21	1.5k	935	762	600	360	67	3.3k
Brian A. Pollok United States	22	2.6k 1.7×	818 0.9×	617 0.8×	429 0.7×	322 0.9×	41	4.0k
Rafael Pulido Spain	38	3.6k 2.4×	1.4k 1.5×	843 1.1×	406 0.7×	273 0.8×	130	5.3k
J. Yun Tso United States	28	2.1k 1.3×	1.3k 1.4×	616 0.8×	775 1.3×	183 0.5×	51	4.3k
Paul S. Changelian United States	27	1.7k 1.1×	1.6k 1.7×	1.5k 1.9×	257 0.4×	333 0.9×	39	4.4k
Christian Stratowa Austria	22	1.5k 1.0×	1.1k 1.1×	438 0.6×	337 0.6×	215 0.6×	28	3.3k
Ted Yednock United States	38	1.9k 1.2×	2.3k 2.4×	1.0k 1.4×	782 1.3×	408 1.1×	78	5.9k
William H. Brissette United States	18	1.5k 1.0×	1.0k 1.1×	687 0.9×	187 0.3×	261 0.7×	25	3.4k
Kris A. Reedquist Netherlands	43	2.9k 1.9×	2.1k 2.2×	1.1k 1.4×	395 0.7×	267 0.7×	91	5.6k
Hrvoje Miletić Norway	40	2.5k 1.6×	707 0.8×	1.1k 1.5×	596 1.0×	280 0.8×	118	5.3k
Laura Sanz Spain	36	4.1k 2.6×	1.4k 1.5×	1.4k 1.9×	746 1.2×	252 0.7×	103	6.3k

Countries citing papers authored by Jonathan Zalevsky

Since Specialization

Citations

This map shows the geographic impact of Jonathan Zalevsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Zalevsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Zalevsky more than expected).

Fields of papers citing papers by Jonathan Zalevsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Zalevsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Zalevsky. The network helps show where Jonathan Zalevsky may publish in the future.

Co-authorship network of co-authors of Jonathan Zalevsky

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Zalevsky. A scholar is included among the top collaborators of Jonathan Zalevsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Zalevsky. Jonathan Zalevsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ahmed, Sairah, John F. DiPersio, James Essell, et al.. (2025). NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. Blood Advances. 9(23). 6092–6095. 1 indexed citations

Ahmed, Sairah, John F. DiPersio, James Essell, et al.. (2025). NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 31(2). S11–S12. 1 indexed citations

Fanton, Christie & Jonathan Zalevsky. (2024). Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases. Allergy. 79(9). 2565–2566. 1 indexed citations

Silverberg, Jonathan I., David Rosmarin, Raj Chovatiya, et al.. (2024). The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nature Communications. 15(1). 9230–9230. 12 indexed citations

Ahmed, Sairah, John F. DiPersio, James Essell, et al.. (2024). NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 144(Supplement 1). 2068–2068.

Tannir, Nizar M., Adi Diab, Mario Sznol, et al.. (2022). Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for ImmunoTherapy of Cancer. 10(4). e004419–e004419. 21 indexed citations

Shah, Nina, Miguel‐Angel Perales, Cameron J. Turtle, et al.. (2021). Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies. Future Oncology. 17(27). 3549–3560. 17 indexed citations

Felip, Enriqueta, David R. Spigel, Óscar Juan, et al.. (2021). 140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC. Annals of Oncology. 32. S1438–S1440. 1 indexed citations

Robinson, Tanya O., Shweta Hegde, Loui Madakamutil, et al.. (2021). NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells. Journal of Clinical Investigation. 131(19). 18 indexed citations

10.

Kopruszinski, Caroline Machado, Yeon Sun Lee, Edita Navratilova, et al.. (2020). Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. Cellular and Molecular Neurobiology. 41(5). 949–960. 8 indexed citations

11.

Veatch, Joshua, et al.. (2020). Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. Journal for ImmunoTherapy of Cancer. 8(2). e001591–e001591. 8 indexed citations

12.

Bentebibel, Salah-Eddine, Michael E. Hurwitz, Chantale Bernatchez, et al.. (2019). A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. Cancer Discovery. 9(6). 711–721. 169 indexed citations

13.

Korver, Wouter, Mary Carsillo, Neeraja Idamakanti, et al.. (2019). A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics. 370(2). 182–196. 22 indexed citations

14.

Diab, Adi, Michael E. Hurwitz, Nizar M. Tannir, et al.. (2017). PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Annals of Oncology. 28. v426–v427. 4 indexed citations

15.

Charych, Deborah H., Vidula Dixit, Peter Kirk, et al.. (2017). Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 12(7). e0179431–e0179431. 111 indexed citations

16.

Chan, Wing Keung, et al.. (2012). Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL -Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands. Clinical Cancer Research. 18(22). 6296–6305. 31 indexed citations

17.

Zalevsky, Jonathan, Aaron K. Chamberlain, Holly M. Horton, et al.. (2010). Enhanced antibody half-life improves in vivo activity. Nature Biotechnology. 28(2). 157–159. 449 indexed citations

18.

Rutschmann, Sophie, Kasper Hoebe, Jonathan Zalevsky, et al.. (2006). PanR1 , a Dominant Negative Missense Allele of the Gene Encoding TNF-α ( Tnf ), Does Not Impair Lymphoid Development. The Journal of Immunology. 176(12). 7525–7532. 17 indexed citations

19.

Oikonomou, Nikos, Vaggelis Harokopos, Jonathan Zalevsky, et al.. (2006). Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis. PLoS ONE. 1(1). e108–e108. 115 indexed citations

20.

Zalevsky, Jonathan, et al.. (2001). Different WASP family proteins stimulate different Arp2/3 complex-dependent actin-nucleating activities. Current Biology. 11(24). 1903–1913. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact